Finally, there are mechanisms of action of these GLP-1s that we don't completely understand." The study is titled, "GLP1 Receptor Agonists and the Risk of Significant Hypotension Among Patients with Metabolic Cardiovascular Renal Disease: Too Much of A Good Thing?"
Repeated treatment can divert money and time from therapies with stronger evidence
NICE Technology Appraisal 875 (Wegovy) and TA664 (Saxenda) recommend these treatments within specialist tier 3 or 4 weight management services for adults with a BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds), with weight-related comorbidities
Treat every draw as a contamination event waiting to happen The stopper is the weak point after reconstitution
For example, Meissner et al 133 conducted a randomized controlled trial evaluating lixisenatide in patients with early stage PD receiving standard treatment